Sahajanand Medical Technologies Ltd.
SMTLMainboard
Ask Iris
Overview
Sahajanand Medical Technologies Limited is an R&D-led medical device manufacturer focused on high-risk cardiovascular implants and consumables across Vascular Intervention (coronary stents, PTCA balloons, drug-coated balloons) and Structural Heart (TAVI valves and occluders). The company operates integrated manufacturing in India and Thailand, sells across a broad international footprint, and positions flagship brands such as Supraflex Cruz (DES), Hydra (TAVI) and Cocoon (occluders) with clinical evidence and global regulatory clearances.
Opening Date
Oct 15, 2026
Closing Date
Oct 19, 2026
Listing Date
Oct 23, 2026
IPO Type
Mainboard
IPO Status
Upcoming
Issue Size
—
Fresh Issue
0 Cr
Offer for Sale
0 Cr
Price Band
—
Lot Size
—
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
Use of IPO funds
Key Performance Indicator
P/E Ratio
—
EPS
6.8
ROE
2.07%
ROCE
3.16%
RONW
2.31%
Debt to Equity Ratio
0.33
PAT Margin
4.29%
EBITDA Margin
13.81%
P/B
—
Bull vs Bear
Bull case
- •
Deep global footprint diversifies demand, so one region’s slowdown is less likely to derail the whole business.
- •
High-risk device categories create tough regulatory and clinical hurdles, so new competitors can’t copy the product set quickly.
- •
Large patent and trademark base can protect designs and branding, helping defend pricing and market access over time.
Bear case
- •
Regulatory approvals and renewals can be slow or withdrawn, so sales and launches can stall and extra testing costs can rise.
- •
Manufacturing issues or low capacity use can raise unit costs, delay deliveries, and damage trust with hospitals and regulators.
- •
Missing historical corporate records could trigger regulatory questions later, creating legal costs and management distraction.
Subscription Rate
Subscription data will be available once the IPO opens.
